Recent Analysts’ Ratings Changes for Johnson & Johnson (JNJ)

Several analysts have recently updated their ratings and price targets for Johnson & Johnson (NYSE: JNJ):

• 7/29/2026 – Johnson & Johnson was given a new $300.00 price target by Argus.
• 7/24/2026 – Johnson & Johnson was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 7/18/2026 – Johnson & Johnson was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/17/2026 – Johnson & Johnson had its “buy” rating reaffirmed by Guggenheim. They now have a $270.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson was upgraded by Johnson Rice from “outperform” to “buy”. They now have a $280.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson had its “outperform” rating reaffirmed by Scotiabank. They now have a $305.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson had its price target raised by Raymond James Financial, Inc. from $258.00 to $265.00. They now have an “outperform” rating on the stock.
• 7/16/2026 – Johnson & Johnson was given a new $261.00 price target by Johnson Rice.
• 7/16/2026 – Johnson & Johnson had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $282.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $284.00 to $294.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – Johnson & Johnson had its price target raised by Wells Fargo & Company from $263.00 to $272.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – Johnson & Johnson was upgraded by Freedom Capital from “hold” to “strong-buy”.
• 7/15/2026 – Johnson & Johnson was given a new $260.00 price target by Stifel Nicolaus.
• 7/13/2026 – Johnson & Johnson had its price target raised by TD Cowen from $250.00 to $300.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Johnson & Johnson had its price target raised by Royal Bank Of Canada from $265.00 to $287.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Johnson & Johnson had its price target raised by Bank of America Corporation from $254.00 to $263.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $283.00 to $284.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $285.00 to $298.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Johnson & Johnson was given a new $290.00 price target by HSBC Holdings plc. They now have a “buy” rating on the stock.
• 6/26/2026 – Johnson & Johnson was given a new $270.00 price target by Johnson Rice.
• 6/26/2026 – Johnson & Johnson had its price target raised by Guggenheim from $266.00 to $270.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Johnson & Johnson was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.